Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03281551 | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | unknown | Phase 1 | 50 | Pinze Lifetechnology Co. Ltd.INDUSTRY | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03208556 | Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 20 | Peking UniversityOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT02822326 | Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | unknown | Phase 1 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT03243643 | Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors(HS:Hansoh;) | unknown | Phase 1 | 80 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2017 | clinicaltrials |
| NCT03276156 | Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer | unknown | Phase 1 | 12 | Zhejiang Cancer HospitalOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT02602249 | Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer. | unknown | Phase 1 | 24 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02656147 | Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 48 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02530398 | A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites | unknown | Phase 1 | 48 | Dongfang Hospital Beijing University of Chinese MedicineOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT03260179 | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 | unknown | Phase 1 | 60 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT03239756 | Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases | unknown | Phase 1 | 40 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02725606 | Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer | unknown | Phase 1 | 30 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03152435 | EGFR CART Cells for Patients With Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | Shenzhen Second People's HospitalOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT03246009 | Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients | completed | Phase 1 | 24 | Tianjin SinoBiotech Ltd.INDUSTRY | 1 | Aug 11, 2017 | clinicaltrials |
| NCT02782351 | Humanized CAR-T Therapy for Treatment of B Cell Malignancy | unknown | Phase 1 / Phase 2 | 50 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Aug 4, 2017 | clinicaltrials |
| NCT03236883 | Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer(HST) | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01551628 | A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma | terminated | Phase 1 | 1 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT02870036 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 243 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT02800369 | Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions | unknown | Phase 1 | 20 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT03207178 | Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma | unknown | Phase 1 / Phase 2 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03166878 | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT02752360 | Biodegradable Stenting Anastomoses Versus Double-layer Hand Sutures for Reconstruction in Intestinal Anastomosis | unknown | Phase 1 | 288 | Beijing Friendship HospitalOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT03189992 | Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science | unknown | Phase 1 | 320 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT03114670 | Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | unknown | Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT03057912 | A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ | unknown | Phase 1 | 60 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03182816 | CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03179007 | CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT02237690 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | completed | Phase 1 | 30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT03164837 | 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | withdrawn | Phase 1 | 0 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT02771470 | Intestinal Microflora in Lung Cancer After Chemotherapy | completed | Phase 1 | 41 | Shandong UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03146533 | CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 20 | Shenzhen Second People's HospitalOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03154775 | Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | unknown | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | May 16, 2017 | clinicaltrials |
| NCT03151447 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer | unknown | Phase 1 | 18 | Fudan UniversityOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02349724 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | unknown | Phase 1 | 75 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03121625 | CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03118180 | CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT03117101 | Study of the AL3810 in the Treatment of Advanced Solid Tumor | completed | Phase 1 | 17 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT02496013 | Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB | unknown | Phase 1 | 70 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT03101709 | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | unknown | Phase 1 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 5, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials